Pharmaceuticals & Therapeutics

With its fibromyalgia drug now on the market, Tonix is expanding its use to MDD, targeting disturbed sleep in a novel approach for millions of patients.

BioCryst is closing its discovery labs to save millions, betting on external partnerships for its next big drug. But what is the hidden cost of this pivot?

The appointment of a supply chain veteran isn't just HR news; it's the key to unlocking a global market for a new heart drug and a lesson in modern strategy.

Merck's new HIV drug, IDVYNSO™, gets a crucial boost via a public health deal, signaling a strategic play to reclaim ground in a multi-billion dollar market.

Larimar Therapeutics is rewriting the rare disease playbook. Its BLA filing for nomlabofusp leverages a novel FDA-aligned endpoint, creating a de-risked path to market.

Beyond the hype, Eisai's latest data on at-home Alzheimer's treatment and a new anti-tau drug signals a seismic shift in patient care and market strategy.

WideTrial's innovative program hit a major milestone, providing 200 ALS patients with an investigational drug and creating a new model for compassionate use.

In a major show of biotech investor confidence, Talawar Therapeutics is going public via a SPAC merger, securing $285M to advance its novel bispecific antibody.

Viridian's Lumvoa gains FDA approval for Thyroid Eye Disease, challenging a blockbuster drug and validating DRI Healthcare's unique royalty investment model.

A German biotech just completed a key trial for a cell therapy that could teach the body to accept a new kidney, freeing patients from a lifetime of harsh drugs.

For over a million Europeans with Parkinson's, a new drug promises longer periods of symptom control. But the path from regulatory approval to patient is complex.

Positive interim data for a world-first CBD insomnia trial de-risks development, promising a safer alternative to current drugs and igniting global interest.

A rare disease drug's EU approval is revoked over 'misleading' data, impacting patients and signaling a new era of strict regulatory scrutiny for pharma giants.

New data on a once-weekly drug and a novel combination therapy signal a major shift in treating achondroplasia, moving the focus from height to quality of life.

As MAPS announces its 2027 summit, the psychedelic field grapples with a critical question: can its visionary promise survive the harsh pressures of reality?

Following promising clinical data, biotech firm Immunis unveils a new brand identity, signaling a strategic shift toward multi-pathway biologics for healthy aging.

ZOIA and Meta Healthcare's alliance brings a ready-to-use liquid nutrition to the US, promising to ease the daily burden for those with a rare metabolic disorder.

Positive Phase 3b data for Otsuka's centanafadine could revolutionize treatment for millions battling both ADHD and anxiety with a single, first-in-class drug.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.